Pharmaceutical

J&J and Legend’s Carvykti scores early line approval for MM by FDA

J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).

Apr 9, 2024 - 00:00
J&J and Legend’s Carvykti scores early line approval for MM by FDA
J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma (MM).
Read the original article

Tags:

Previous Article

Pluri launches manufacturing division as cell therapy pipeline progresses

Next Article

Pharmaceutical solid dose (commercial dose) manufacturing companies in contract ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘Hard to catch up’: FDA commissioner on regulating new digital health tools

STAT+: ‘Hard to catch up’: FDA commissioner on regulati...

May 9, 2023

STAT+: Bellerophon Therapeutics trial fails despite innovative digital endpoint

STAT+: Bellerophon Therapeutics trial fails despite inn...

Jun 6, 2023

FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor  

FDA lifts partial clinical hold on Zentalis Pharma’s ca...

Sep 18, 2024